Study for Adolescents and Adults With Ornithine Transcarbamylase Deficiency to Evaluate Safety and Tolerability of ARCT-810

Stopped The study was terminated after the completion of Cohort 1 (0.3 mg/kg) due to slow enrollment in this placebo-controlled study.

Conditions

• Ornithine Transcarbamylase Deficiency
• OTC Deficiency
• OTCD

Interventions

• BIOLOGICAL: ARCT-810
• OTHER: Placebo

Sponsor

Arcturus Therapeutics, Inc.